论文部分内容阅读
目的:探讨Krüppel样转录因子12(Krüppel-like factor12,KLF12)在子宫颈腺癌中的表达及与临床特征的关系,为寻找新的子宫颈腺癌预后标志物及治疗靶点提供依据。方法:收集增城市妇幼保健院2005-2007年92例子宫颈腺癌患者的肿瘤组织标本,采用免疫组织化学染色法分析KLF12在子宫颈腺癌中的表达。Kaplan-Meier及Log-rank法分析KLF12表达水平与患者5年生存率的关系。Mann-Whitney U检验分析KLF12表达水平高低与患者临床特征之间的关系。Cox比例风险回归模型分析KLF12表达水平及其他临床特征与患者预后的关系。结果:KLF12在大部分子宫颈腺癌患者中高表达(69/92),高表达KLF12的子宫颈腺癌患者5年生存率明显低于KLF12低表达患者(P<0.001)。KLF12高表达与子宫颈腺癌患者的临床分期(P=0.01)、淋巴结转移(P<0.001)和宫旁浸润(P<0.001)存在明显的相关性。KLF12高表达是子宫颈腺癌患者预后不良的独立预测指标(HR=4.117,P=0.001)。结论:KLF12在子宫颈腺癌中可能是一个癌基因,并有可能作为子宫颈腺癌患者预后分子标志物和新的治疗靶点。
OBJECTIVE: To investigate the expression of Krüppel-like factor 12 (KLF12) in cervical adenocarcinoma and its relationship with clinical features, and to provide evidence for searching for new cervical adenocarcinoma prognostic markers and therapeutic targets. Methods: Tumor samples of 92 cases of cervical adenocarcinoma from 2005 to 2007 in the MCH hospital were collected and the expression of KLF12 in cervical adenocarcinoma was analyzed by immunohistochemical staining. Kaplan-Meier and Log-rank analysis of KLF12 expression level and the relationship between 5-year survival rate. Mann-Whitney U test analysis of KLF12 expression levels and the relationship between the clinical features of patients. Cox proportional hazards regression model was used to analyze the relationship between the expression of KLF12 and other clinical features and the prognosis of patients. Results: The 5-year survival rate of KLF12 was significantly higher in patients with cervical adenocarcinoma (69/92) than in those with low KLF12 expression (P <0.001). There was a significant correlation between KLF12 overexpression and clinical stage (P = 0.01), lymph node metastasis (P <0.001) and parametrial infiltration (P <0.001) in patients with cervical adenocarcinoma. High expression of KLF12 is an independent predictor of poor prognosis in patients with cervical adenocarcinoma (HR = 4.117, P = 0.001). Conclusion: KLF12 may be an oncogene in cervical adenocarcinoma and may be used as a prognostic molecular marker and a new therapeutic target for cervical adenocarcinoma.